Mega Lifesciences Beheer

Beheer criteriumcontroles 2/4

De CEO Mega Lifesciences is Vivek Dhawan, benoemd in Jan1988, heeft een ambtstermijn van 36.83 jaar. bezit rechtstreeks 6.59% van de aandelen van het bedrijf, ter waarde THB 2.18B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 26.8 jaar en 11.8 jaar.

Belangrijke informatie

Vivek Dhawan

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	36.8yrs
Eigendom CEO	6.6%
Management gemiddelde ambtstermijn	26.8yrs
Gemiddelde ambtstermijn bestuur	11.8yrs

Recente managementupdates

Recent updates

CEO

Vivek Dhawan (63 yo)

36.8yrs

Tenure

Mr. Vivek Dhawan is CEO, Chief Coach & Executive Director of Mega Lifesciences Public Company Limited from 2013. He joined the Mega Lifesciences Public Company Limited in 1986. He is CEO & Chief Coach of M...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Vivek Dhawan	CEO, Chief Coach & Executive Director	36.8yrs	geen gegevens	6.59% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.8yrs	geen gegevens	0.76% THB 253.4m
Deepak Panjwani	Chief Risk & Compliance Officer	no data	geen gegevens	geen gegevens
Paramjit Sawhney	President of International	no data	geen gegevens	1.5% THB 497.2m
Girish Wadhwa	President of Myanmar	no data	geen gegevens	geen gegevens
Manoj Gurbuxani	Deputy Chief Financial Officer	4.8yrs	geen gegevens	geen gegevens
Duangnapa Tongsiri	President of Mega We Care Thailand	no data	geen gegevens	1.48% THB 489.6m
Sujintana Boonworapat	Corporate Secretary	no data	geen gegevens	geen gegevens

26.8yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MEGA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 26.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Vivek Dhawan	CEO, Chief Coach & Executive Director	11.8yrs	geen gegevens	6.59% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.8yrs	geen gegevens	0.76% THB 253.4m
Yim Chi	Independent Vice Chairma	11.8yrs	฿1.58m	geen gegevens
Kirit Chimanlal Shah	Non-Executive Director	11.8yrs	฿661.50k	49.81% THB 16.5b
Shiraz Poonevala	Non-Executive Director	11.8yrs	฿661.50k	geen gegevens
Ishaan Shah	Non-Executive Director	11.8yrs	฿661.50k	geen gegevens
Mechai Viravaidya	Independent Chairman	11.8yrs	฿2.21m	geen gegevens
Sameera Shah	Non-Executive Director	11.8yrs	฿661.50k	geen gegevens
Thor Santhisiri	Independent Director	11.8yrs	฿1.15m	geen gegevens
Vijay Karwal	Independent Director	3.5yrs	฿1.15m	geen gegevens
Nithinart Sinthudeacha	Independent Director	1.8yrs	฿1.15m	geen gegevens

11.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MEGA zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.8 jaar).

Mega Lifesciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Recent updates

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd